Weimin Tang, PhD.
Executive Director, Global Business Development & Licensing
Dr. Weimin Tang serves as our Executive Director of Global Business Development. Previously, Dr. Tang served as Vice President of global business development and drug discovery at Crown Bioscience, Prior to Crown Bioscience, Dr. Tang served as Principal Scientist of Johnson and Johnson Research from 2002 to 2010. Over the course of his career, Dr. Tang has served Synaptic Pharmaceuticals (now Lundbeck Pharmaceuticals), American Cyanamid (now Pfizer); Bristol Myer Squibb, Hoechst (now Sanofi) with varies function in research and development. Dr. Tang received a Bachelor’s Degree from Zhejiang University, Master Degree from Chinese Academy of Sciences and PhD from Rutgers University.
T. Angela Hu, PhD.
Director, Regulatory Affairs and Translational Medicine
Dr. Angela Hu has over twelve years of pharmaceutical R&D experience in multiple therapeutic areas including oncology, cardiovascular disease and musculoskeletal disorder. She has led multidisciplinary teams in advancing several small-molecule and large-molecule projects to achieve important milestones, including delivery of a clinical candidate that is currently undergoing phase II clinical trials. In her new role as Regulatory Affairs and Translational Medicine at HTI, Dr. Hu is responsible for strategic and operational aspects of regulatory document submission, in addition to her responsibility for translational strategies supporting early drug development.
Dr. Hu holds a PhD. in Molecular and Cellular Biology from the University of Texas at Dallas.